HomeCompareMCDA vs PFE

MCDA vs PFE: Dividend Comparison 2026

MCDA yields 2000000.00% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MCDA wins by $4.879226400974806e+39M in total portfolio value
10 years
MCDA
MCDA
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full MCDA calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — MCDA vs PFE

📍 MCDA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMCDAPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MCDA + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MCDA pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MCDA
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, MCDA beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MCDA + PFE for your $10,000?

MCDA: 50%PFE: 50%
100% PFE50/50100% MCDA
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

MCDA
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MCDA buys
0
PFE buys
0
No recent congressional trades found for MCDA or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMCDAPFE
Forward yield2000000.00%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$4.879226400974806e+39M$49.6K
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$26,258.71
Total dividends collected$4.879195005460081e+39M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MCDA vs PFE ($10,000, DRIP)

YearMCDA PortfolioMCDA Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$200,010,700$200,000,000.00$9,153$693.39+$200.00MMCDA
2$3,738,731,768,458$3,738,517,757,009.35$8,593$849.25+$3738731.76MMCDA
3$65,315,062,866,930,490$65,311,062,423,938,240.00$8,336$1,066.78+$65315062866.92MMCDA
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$8,437$1,384.80+$1066400830062625.00MMCDA
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$9,013$1,875.40+$16272182796453826560.00MMCDA
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$10,306$2,680.72+$2.3205424011366188e+23MMCDA
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$12,820$4,101.38+$3.0927990661046884e+27MMCDA
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$17,673$6,826.70+$3.8524105697352695e+31MMCDA
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$27,543$12,591.86+$4.484688260147987e+35MMCDA
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$49,560$26,258.71+$4.879226400974806e+39MMCDA

MCDA vs PFE: Complete Analysis 2026

MCDAStock

KMA Holding, Inc., through its subsidiaries, manufactures human and pet home medical test kits and emergency response mobile hospital units in the United States. The company focuses on the detection of various illnesses, such as cancer, through the analysis of blood, saliva, urine, hair, and other substances. It offers home screening medical detection test kits for drugs of abuse, sexually transmitted diseases, infectious deceases, tumor marker, and fertility. The company also provides pet home medical test kits for cancer, diabetics, and lime diseases. In addition, it offers emergency medical response mobile hospital units, which enable the provision of temporary emergency life support, and medical and pharmaceutical products and services; and communication via secured wireless technology. The company was formerly known as Macada Holding, Inc. and changed its name to KMA Holding, Inc. in March 2011. KMA Holding, Inc. was founded in 2000 and is based in Pompano Beach, Florida.

Full MCDA Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this MCDA vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MCDA vs SCHDMCDA vs JEPIMCDA vs OMCDA vs KOMCDA vs MAINMCDA vs JNJMCDA vs MRKMCDA vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.